Track market-moving stories before they get noisy

Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products.

New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE: CC) and certain of the company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.

Key Details of the Chemours ($CC) Class Action:

Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products Stock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rightsInvestors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.

Why is Chemours Being Sued for Securities Fraud?

Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.

According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by "higher . . . demand" in its Opteon segment.

As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an "oversupplied channel heading into 2026."

Why did Chemours's Stock Drop?

On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had "built additional inventory" of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an "oversupplied channel heading into 2026."

On this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.

Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.

What Can You Do?

If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/chemours-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/chemours-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320500

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Promise vs. Reality: The Chemours Performance Gap. Management cited "very stable volume" in May, but the lawsuit alleges an oversold Opteon aftermarket channel was already eroding 2026 demand.

, /PRNewswire/ -- Levi & Korsinsky, LLP highlights the alleged Chemours promise-reality gap at the center of a securities fraud class action pending on behalf of investors who suffered losses after purchasing The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026. Check if you might be eligible to recover your investment losses, or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

The promise, delivered by management in May, was "very stable volume" and a reaffirmed full-year adjusted EBITDA outlook of $800 million to $900 million. The reality came on August 4, 2026, when the Company reported a 4% volume decline and cut that outlook to $775 million to $825 million, and the next day shares fell $3.34, or 18.63%, to close at $14.59. LEAD PLAINTIFF DEADLINE: December 7, 2026.

The Promise

Opteon refrigerants were cast as the Company's growth engine throughout the first half of 2026. In February, the Company projected that double-digit year-over-year Opteon Refrigerant growth would continue into the second quarter. By the first-quarter call, management was claiming "a really, really strong position in the aftermarket" and reaffirming 3% to 5% full-year net sales growth.

Promise vs. Actual: By the Numbers

Volume: "Very stable," according to management in May. Company-wide second-quarter volumes fell 4%. Net sales: Full-year growth of 3% to 5% promised. Second-quarter net sales came in at $1.6 billion, down approximately 1% year over year. Opteon trajectory: Double-digit growth projected into the second quarter. The August results instead identified lower Opteon blends aftermarket sales as the primary driver of the volume decline. Aftermarket demand: Management saw "a lot of upside in the aftermarket as new equipment gets installed." The Company later compared aftermarket sales against "elevated demand" in the prior-year quarter tied to the initial channel fill. Full-year earnings: Adjusted EBITDA of $800 million to $900 million, reaffirmed in May. Cut to $775 million to $825 million in August, removing $75 million from the top of the range. What the Lawsuit Alleges About the Chemours Promise-Reality Gap

Plaintiffs contend that the gap shows these assurances were given while Opteon aftermarket demand was already declining because the Company had oversold product in 2025. The complaint alleges that customer prebuy and initial channel fill pulled sales out of 2026, leaving the original guidance without a reasonable basis. Investors who paid prices allegedly inflated by those statements absorbed the decline once the shortfall surfaced.

"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. The complaint alleges Chemours described its volume as very stable roughly three months before reporting a 4% decline. Shareholders who relied on that assurance deserve answers about what was known when it was given." -- Joseph E. Levi, Esq.

Learn more about the case or call (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com | Attorney Advertising. Prior results do not guarantee similar outcomes.

Frequently Asked Questions About the CC Lawsuit

Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements during the Class Period regarding aftermarket demand for its Opteon refrigerants, the effect of 2025 overselling on 2026 demand, and the reliability of its 2026 financial guidance. When Chemours cut its full-year adjusted EBITDA guidance and attributed lower Opteon aftermarket sales to an oversupplied channel, the stock price declined sharply.

Q: When did Chemours allegedly mislead investors? A: The Class Period runs from February 20, 2026 to August 4, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the CC class action filed in? A: The case was filed in the United States District Court for the District of Delaware, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in Chemours and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 7, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, on August 4, 2026, after market, Chemours announced second quarter 2026 financial results. Among other things, the Company allegedly reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management allegedly admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; and (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/the-chemours-company-cc-class-action/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320133

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Action reflects Chemours' commitment to innovation, intellectual property protection, our customers, and fair competition in the refrigerants industry

, /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC), a global chemistry company, today announces that it has taken action to protect its intellectual property relating to refrigerant technology during Chillventa 2026 in Nuremberg, Germany. Local courts issued injunctions against four companies infringing upon Chemours' intellectual property and patents of select hydrofluoroolefin (HFO) refrigerant blends.

This action showcases Chemours' unwavering commitment to protecting its innovation and intellectual property investments in advanced refrigerant technologies and across applications. Enforcing intellectual property rights supports industry-wide innovation, fair competition, our customers, and continued technology development.

"Innovation does not happen by accident; it is built on years of research, development, and investment," said Joseph Martinko, President, Thermal & Specialized Solutions at Chemours. "Protecting intellectual property is essential to preserving incentives for innovation, advancing refrigerant technology, and supporting fair competition. Chemours will continue to take appropriate action to defend its intellectual property rights and protect the innovations that help our customers meet evolving industry needs."

Chemours is actively working with enforcement authorities around the globe and educating customers, vendors, and other stakeholders to raise awareness about these Patent Infringing products and the importance of buying genuine refrigerants.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, new product development, technologies protected by intellectual rights, governing laws and rule regarding the enforcement of intellectual property rights and patent protections, , plans to continue investment in research and development, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, regulatory changes, and changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law. 

CONTACTS:

INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300 
[email protected] 

NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected] 

SOURCE The Chemours Company

Did you buy CC securities between February 20, 2026 and August 4, 2026?

Affected CC Investor Summary

Who: The Chemours Company (NYSE: CC)What: Securities fraud class action lawsuit filedClass Period: February 20, 2026 through August 4, 2026Deadline to Seek Lead Plaintiff Status: December 7, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the reliability of the company’s financial guidanceInvestor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against The Chemours Company (“Chemours”) (NYSE: CC) on behalf of those who purchased or acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Delaware and is captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.). Investors have until December 7, 2026, to file for lead plaintiff status.  

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Chemours securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/cc-the-chemours-company-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=cc&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.

THE CHEMOURS COMPANY CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Chemours is an American chemical company that offers a range of industrial and specialty chemical products for markets including, but not limited to, refrigeration and air conditioning. Chemours’s Thermal & Specialized Solutions (“TSS”) segment sells its product OpteonTM, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint.”

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHY DID CHEMOURS’S STOCK DROP?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results, revealing, among other things, that the company reduced its adjusted EBITDA full year guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and its year-over-year net sales decrease of approximately 1%, to a “4% decrease in volumes.” Specifically, it stated that “[t]he volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales.”

On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

WHAT THE CHEMOURS COMPANY INVESTORS CAN DO NOW:

File to be lead plaintiff by December 7, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR THE CHEMOURS COMPANY INVESTORS:
Chemours investors may, no later than December 7, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Chemours investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.

CONTACT:

Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

        May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

New York, New York--(Newsfile Corp. - October 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.

Chemours Case Details

The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:

Defendants had materially overstated aftermarket demand for their Opteon products; demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and as a result, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Chemours Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Chemours Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318448

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Resolves litigations brought by the State of North Carolina and 11 local entities relating to PFAS and other historical discharges from Fayetteville Works, as well as the State's claims of PFAS contamination unrelated to that site, including from the use of aqueous film forming foam ("AFFF"). Overall settlement payments total $455 million over 15 years; Chemours' 50% share of payments of approximately $180 million on a net present value basis, which are covered by existing accruals. The settlement recognizes the significant investments and progress made under the 2019 Consent Order with the State of North Carolina, including substantial reductions in PFAS emissions from Fayetteville Works and mitigation of off-site impacts in the surrounding communities. , /PRNewswire/ -- The Chemours Company (NYSE: CC) (the "Company") today announced that, along with DuPont de Nemours, Inc. ("Dupont") and Corteva, Inc. ("Corteva"), it has entered into a settlement (the "Settlement") with the State of North Carolina (the "State") and 11 local entities* in the vicinity of the Company's Fayetteville Works facility that were excluded from the U.S. Public Water System Class Settlement approved in 2024.

The Settlement resolves litigations brought by the State and the settling local entities relating to PFAS and other historical discharges from Fayetteville Works, as well as the State's claims of PFAS contamination unrelated to that site, including from the use of AFFF.

The settlement also acknowledges the substantial progress made under the Company's 2019 Consent Order with the State (the "Consent Order"). Since 2019, Chemours has made substantial investments to significantly reduce PFAS emissions from Fayetteville Works and mitigate off-site impacts in the surrounding communities. The agreement recognizes that several Consent Order provisions have been completed and establishes procedures to address certain remaining obligations relating to off-site areas, including implementation of drinking water programs.

Settlement payments will total $455 million (the "Settlement Amount") over a 15-year period beginning within 30 days of the execution date of the agreement. Chemours' share of expected payments over the next twelve months is approximately $50 million. Of the total settlement amount, $18 million is attributed to alleged PFAS contamination unrelated to Fayetteville Works.

The terms of the Settlement, including a further description of claims released and not released, are set forth in the Settlement Agreement, which remains subject to entry of dismissals of the covered litigations.

Consistent with the January 2021 Memorandum of Understanding ("MOU") between the Company, DuPont, and Corteva, Chemours will be responsible for 50% of settlement payments, and DuPont and Corteva will be responsible for the remaining 50%. In addition, Chemours, DuPont, and Corteva have mutually worked together to reach certain understandings concerning the MOU, including the valuation of the Settlement and potential future multi-year settlements on a net present value basis for purposes of calculating qualified spend, as they continue to work together to address legacy PFAS-related litigation matters. Pursuant to these understandings, for purposes of calculating the amount of qualified spend, the Settlement Amount will account for approximately $210 million.

In addition, all future contributions to the MOU escrow account will be considered satisfied, including Chemours' $50 million escrow contribution that would have been due in September 2026. 

This settlement marks further progress under the Strengthening the Long-Term Pillar of Chemours' Pathway to Thrive strategy and ongoing efforts to address legacy liabilities and community concerns. The agreement provides greater clarity regarding the liabilities associated with these matters, acknowledges the significant progress already made at Fayetteville Works, and supports the Company's continued operation of this important manufacturing facility.

* The 11 local entities are Bladen County, Brunswick County, Columbus County, Cumberland County, New Hanover County, Robeson County, Sampson County, Town of Wrightsville Beach, City of Lumberton, Village of Bald Head Island, and Lower Cape Fear Water and Sewer Authority.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. 

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about expected performance and impact of the cost-sharing arrangements by and between Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Factors that could cause or contribute to these differences include, but are not limited to: the relevant courts' entry of dismissals required for the Settlement Agreement to become final; the outcome of any pending or future litigation related to PFAS or PFOA, including claims by North Carolina subdivisions not covered by the settlement, personal injury claims, property damage claims, and natural resource damages claims; the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of remaining obligations under the Consent Order; changes in laws and regulations applicable to PFAS chemicals; the performance by each of the parties of their respective obligations under the MOU. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Further lists and descriptions of risks and uncertainties can be found in Chemours' annual report on Form 10-K for the year ended December 31, 2025 and subsequent reports on Form 10-Q and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Chemours' consolidated financial condition, results of operations, credit rating or liquidity. Chemours does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

CONTACTS:

INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
[email protected]

NEWS MEDIA 
Jess Loizeaux
Communications Leader, External Affairs
+1.302.685.8554
[email protected] 

SOURCE The Chemours Company

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Chemours and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.” 

On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 10, 2026.

Then, on August 11, 2026, AECOM reported weaker-than-expected results for the third quarter of 2026, which were impacted by a $337 million pre-tax loss related to the delayed completion of a construction management project. 

On this news, AECOM’s stock price fell $6.25 per share, or 8.53%, to close at $67.05 per share on August 11, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Key Takeaways Chemours cut its Q2 net loss to $274 million, while adjusted EPS fell short of estimates. Sales fell 1% as a 4% volume decline offset higher pricing and favorable currency impacts. Chemours expects Q3 EBITDA of $175-$205 million and 2026 sales growth of 1-5%. The Chemours Company (CC - Free Report) reported a net loss of $274 million or a loss of $1.81 per share for the second quarter of 2026. This compares favorably with the year-ago quarter’s net loss of $380 million or a loss of $2.53 per share. 

Barring one-time items, earnings were 42 cents per share, which missed the Zacks Consensus Estimate of 43 cents by roughly 2.3%. Adjusted earnings also declined from 61 cents per share in the year-ago quarter. 

The company reported second-quarter net sales of $1,591 million, reflecting a 1% decrease from the previous-year quarter. The figure missed the Zacks Consensus Estimate of $1,674.1 million by roughly 5%. Net sales were affected by a 4% decrease in volumes, partly offset by a 2% increase in price and a 1% favorable currency impact. 

Adjusted EBITDA declined 5% year over year to $247 million for the quarter from $260 million. The decrease was due to higher costs in Advanced Performance Materials (APM) associated with the Washington Works outage and lower sales following the SPS Capstone line closure, partly offset by pricing increases across all segments. 

The Chemours Company Price, Consensus and EPS SurpriseCC’s Segment HighlightsThe Titanium Technologies (TT) division recorded revenues of $661 million in the second quarter, marking a 1% increase from the previous year. The figure missed our estimate of $663.6 million. The year-over-year increase was driven by a 2% rise in global pricing and a 1% currency tailwind, which more than offset a 2% decline in global volumes. 

In the Thermal & Specialized Solutions (TSS) segment, revenues decreased 1% year over year to $591 million in the reported quarter. The figure missed our estimate of $637.3 million. The decline was due to a 4% fall in volumes, partly offset by a 2% increase in price and a slight currency tailwind. Lower volumes primarily reflected weaker North American stationary AC aftermarket sales of Opteon blends compared with elevated demand in the prior-year quarter. 

TSS adjusted EBITDA increased 3% year over year to $213 million, while adjusted EBITDA margin improved one percentage point to 36%, aided by higher pricing and the timing of certain costs. 

Revenues in the APM unit amounted to $326 million, which declined 6% year over year. The figure missed our estimate of $338.2 million. The downside was mainly caused by a 9% decrease in volumes, partly offset by a 2% increase in price and a slight currency tailwind. The volume decline primarily reflected the SPS Capstone line closure, while Performance Solutions sales rose 8% year over year on strength in data center and semiconductor end markets. 

CC’s FinancialsOperating cash flow in the second quarter was $158 million compared with $93 million in the year-ago quarter. Capital expenditures were $44 million compared with $43 million in the prior-year quarter. Free cash flow increased to $114 million from $50 million a year earlier. 

As of June 30, 2026, Chemours had consolidated gross debt of $3.9 billion. Debt, net of $671 million in unrestricted cash and cash equivalents, was $3.2 billion. Total liquidity was $1.6 billion, and the net leverage ratio was approximately 4.4. 

CC’s OutlookFor the third quarter, the company expects consolidated net sales to decline in the range of 5% to flat sequentially. Consolidated adjusted EBITDA is expected to be in the range of $175-$205 million. Corporate expenses are expected to be $40-$45 million. The company also expects capital expenditures of around $65 million and free cash flow of at least $50 million. 

Chemours expects TSS’ net sales to decrease sequentially in the mid-teens to 20% range in the third quarter, reflecting less favorable seasonality and weaker Opteon blends aftermarket demand. Adjusted EBITDA is projected to be between $125 million and $140 million. 

TT’s net sales are expected to increase sequentially in the low-to-mid-single-digit percentage range, driven by recent pricing announcements, with stable volumes. Adjusted EBITDA is expected to be in the range of $70-$80 million. 

APM’s net sales are expected to increase sequentially in the mid-to-high-single-digit percentage range, driven by normalized operations at Washington Works and continued strength in Performance Solutions. Adjusted EBITDA for APM is expected to be between $20 million and $30 million. 

For 2026, Chemours expects net sales to grow in the range of 1-5% year over year and adjusted EBITDA of $775-$825 million. Capital expenditures are expected in the range of $250-$280 million, with free cash flow conversion above 25%. The company continues to target a net leverage ratio of around 3.8x by year-end 2026. 

CC’s Price PerformanceChemours’ shares have gained 17.4% in the past year compared with the 6.8% rise of the industry.

Image Source: Zacks Investment Research

CC’s Zacks Rank & Key PicksCC currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks are Almonty Industries Inc. (ALM - Free Report) , ClearSign Technologies Corporation (CLIR - Free Report)  and Applied Industrial Technologies, Inc. (AIT - Free Report) .  

Almonty is expected to report second-quarter results on Aug. 13. The Zacks Consensus Estimate for ALM’s second-quarter earnings is pegged at 10 cents per share. It carries a Zacks Rank #2 (Buy) at present. 

ClearSign is scheduled to report second-quarter 2026 results on Aug. 19. The consensus estimate for CLIR’s loss per share is pegged at 25 cents. CLIR presently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Applied Industrial is scheduled to report fourth-quarter fiscal 2026 results on Aug. 13. The Zacks Consensus Estimate for AIT’s fourth-quarter earnings per share is pegged at $2.92. AIT carries a Zacks Rank #2 at present. 

Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand RisesChemours NYSE: CC said its second-quarter results reflected pricing gains, operational improvements and continued execution under its Pathway to Thrive strategy, while softer residential air-conditioning aftermarket demand weighed on sales in its Thermal & Specialized Solutions business.

President and Chief Executive Officer Denise Dignam said second-quarter net sales came in slightly below the company’s expectations, primarily because of softer residential stationary air-conditioning demand in Thermal & Specialized Solutions, or TSS. However, adjusted EBITDA exceeded expectations, helped by stronger operations and product mix in Advanced Performance Materials, lower corporate costs and pricing gains in Titanium Technologies.

Get Chemours alerts:

MarketBeat Week in Review – 06/22 - 06/26“The actions we are taking under Pathway to Thrive are strengthening the business,” Dignam said, citing pricing actions, debt reduction, cash generation and recent settlements with the U.S. Environmental Protection Agency and West Virginia Department of Environmental Protection.

Aftermarket destocking pressures TSS outlook TSS net sales were slightly lower than a year earlier, as lower North American aftermarket sales of Opteon refrigerant blends offset year-over-year growth in OEM volumes and continued growth in data-center-related markets. Higher prices, including strength in Freon refrigerants used primarily in automotive applications, partly mitigated the volume decline.

Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereDignam said the prior-year period benefited from distributor channel filling connected to the U.S. AIM Act transition in stationary air conditioning. That inventory build left the aftermarket with elevated stock entering 2026.

The company said residential demand has also been constrained by higher interest rates, affordability pressures and slower housing activity. A colder spring in the Northeast and broader macroeconomic uncertainty contributed to weaker order activity, executives said.

For the third quarter, Chemours expects TSS net sales to decline sequentially by the mid-teens to 20% range, with adjusted EBITDA of $125 million to $140 million. CFO Shane Hostetter said the outlook reflects seasonal factors and a less favorable mix from lower Opteon aftermarket sales.

Hostetter said the company still views TSS as a business capable of margins above 30% over time. He said the company expects seasonal restocking to begin ahead of the 2027 cooling season, while the expanding installed base of newer residential and light-commercial systems should support longer-term growth.

Chemours expects the stationary aftermarket to grow at a mid- to high-single-digit annual percentage rate over the longer term, supported by equipment replacement activity, heat-pump adoption in Europe and data-center chiller demand.

Titanium Technologies pricing offsets inflation In Titanium Technologies, second-quarter net sales increased slightly from the prior-year quarter, driven primarily by global pricing gains. Volumes declined in key end markets, except in Asian markets excluding China and in Latin America, where demand was more resilient following antidumping duties in Brazil.

Adjusted EBITDA improved year over year, while adjusted EBITDA margin was flat. Chemours said higher pricing more than offset inflation-related costs.

The company has announced three titanium dioxide price increases since December 2025, including a global increase effective June 1. Together, the actions have resulted in an approximately 5% year-to-date increase in pricing compared with the start of the year, according to management.

For the third quarter, Chemours expects Titanium Technologies net sales to rise sequentially in the low- to mid-single-digit percentage range and adjusted EBITDA to total $70 million to $80 million. The company expects volumes to be higher year over year in the second half across all end markets outside China.

Dignam said rising sulfur costs are increasing costs for sulfate-produced titanium dioxide, a trend that predated the war and has since intensified. She said the company remains focused on “fair trade markets” where it believes customers value supply reliability and its product offering.

APM sees data center and semiconductor momentum Advanced Performance Materials sales declined year over year in the second quarter, largely because of the SPS Capstone line closure completed in the third quarter of 2025. Higher prices partially offset the volume impact. Adjusted EBITDA also declined, reflecting the line closure and costs related to the now-resolved Washington Works outage.

Within APM, Performance Solutions sales increased 8% from the prior-year period. Dignam said the business is benefiting from order-book strength in data center and semiconductor applications. More than 40% of Performance Solutions sales are tied to targeted markets including data centers, semiconductors, artificial intelligence and advanced electronics, management said.

Chemours recorded nominal sales of two-phase liquid-cooling products for customer sampling during the quarter. Product trials increased 70% year over year, according to the company. Dignam said commercial liquid cooling today is primarily single-phase, while two-phase liquid cooling represents a potential future opportunity.

For the third quarter, Chemours expects APM sales to increase sequentially in the mid- to high-single-digit percentage range, supported by normalized operations at Washington Works and Performance Solutions order fulfillment. Adjusted EBITDA is expected to be $20 million to $30 million, including about $5 million of sales performance pulled forward into the second quarter.

Full-year outlook and debt reduction Chemours expects third-quarter consolidated net sales to range from down 5% sequentially to flat, with adjusted EBITDA of $175 million to $205 million. Corporate expenses are expected to be approximately $40 million to $45 million, capital expenditures are expected to be about $65 million, and free cash flow is projected to be at least $50 million.

Full-year 2026 net sales are expected to grow 1% to 5% from 2025. Full-year adjusted EBITDA is projected at $775 million to $825 million. Capital expenditures are expected to total $250 million to $280 million. Free-cash-flow conversion is expected to exceed 25%. Net leverage is expected to be about 3.8 times adjusted EBITDA by year-end 2026. The company repaid nearly $270 million of its 2028 euro term loan during the second quarter, including $103 million beyond the amount discussed on its first-quarter call. Hostetter said Chemours intends to continue prioritizing debt repayment through organic cash flow and proceeds received from the Kuan Yin land sale.

Looking beyond 2026, Dignam said Chemours is pursuing strategic and portfolio optionality, including potential partnerships and actions involving product lines or assets. She said no portfolio action is off the table if it could create a “step change” in shareholder value, though she declined to discuss specific potential transactions.

The company said its core businesses could ultimately support at least $1 billion in annual adjusted EBITDA and free-cash-flow conversion exceeding 40%, while it continues to reduce balance-sheet risk.

About Chemours (NYSE:CC)Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Chemours Right Now?Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

, /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the second quarter 2026.

Key Second Quarter 2026 Results & Recent Highlights1

Net Sales of $1.6 billion, approximately flat compared to the corresponding prior-year quarter reflecting pricing increases across all businesses Net Loss attributable to Chemours of $274 million, or $1.81 per diluted share, compared with Net Loss attributable to Chemours of $380 million, or $2.53 per diluted share, in the corresponding prior-year quarter Adjusted Net Income2 of $64 million, or $0.42 per diluted share, compared to Adjusted Net Income of $91 million, or $0.61 per diluted share, in the corresponding prior-year quarter Adjusted EBITDA2,3 of $247 million compared to $260 million in the corresponding prior-year quarter, reflecting a strong prior-year comparison from TSS aftermarket performance Free Cash Flows improved 128% year-over-year, with Free Cash Flow Conversion of 46% and net leverage declining to 4.4x, advancing Chemours toward its long-term target of sustaining leverage below 3x Announced an additional global TiO2 price increase effective June 1, 2026, contributing to an approximately 5% year-to-date TiO2 price increase in Net Sales APM Performance Solutions Net Sales grew 8% year-over-year, underscoring momentum and mix shift towards high-value specialty products serving data center and semiconductor end market "Our second quarter results reflect disciplined execution across our portfolio, with Adjusted EBITDA near the high end of our guidance range and Free Cash Flows above our expectations despite a dynamic macroeconomic environment," said Denise Dignam, Chemours President and CEO. "Progress on pricing actions in Titanium Technologies to drive value, and increased sales in APM's high-value Performance Solutions portfolio supporting our momentum serving data center and semiconductor applications, and continued traction in our liquid cooling solutions, highlight our efforts to drive commercial excellence and growth."

Dignam continued, "Chemours also made meaningful progress strengthening its balance sheet through improved cash generation and reduced gross debt, while advancing resolution of notable legacy litigation. Looking ahead to the second half of the year, we remain focused on the actions within our control and committed to executing against our Pathway to Thrive strategy."

Total Chemours

Q2 2026

Q2 2025

Y-o-Y % ∆

Q1 2026

Q-o-Q % ∆

Net Sales (millions)

$1,591

$1,615

(1) %

$1,381

15 %

Net Income (Loss) attributable to
Chemours (millions)

($274)

($380)

28 %

($29)

(845 %)

Earnings (Loss) Per Share4

($1.81)

($2.53)

28 %

($0.19)

(853 %)

Adjusted Net Income

$64

$91

(30 %)

$8

700 %

Adjusted EPS

$0.42

$0.61

(31 %)

$0.05

740 %

Adjusted EBITDA (millions)

$247

$260

(5) %

$169

46 %

Second quarter 2026 Net Sales were approximately $1.6 billion, a decrease of approximately 1% compared to the prior-year quarter. The year-over-year decrease in Net Sales was driven by a 4% decrease in volumes, partially offset by a 2% increase in price and a 1% currency tailwind. The volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with stationary technology AC transition under the U.S. AIM Act, as well as lower volumes associated with the APM SPS Capstone™ line closure completed in the third quarter of 2025. These volume headwinds were partially offset by pricing strength across all three segments, including price increases in TT.

Second quarter 2026 Net Loss attributable to Chemours was ($274) million, or ($1.81) per diluted share, compared to Net Loss attributable to Chemours of ($380) million, or ($2.53) per diluted share, in the prior-year quarter. The prior-year second quarter loss includes the impact of the announced settlement with the State of New Jersey and related legal and environmental reserves recognized and corresponding tax impacts, while the current-year second quarter loss includes the impact of legal and environmental reserves related to the announced settlement with the EPA and WVDEP as well as ongoing litigation, and corresponding tax impacts, partially offset by a gain on the Kuan Yin property sales. Second quarter Adjusted Net Income decreased compared with the prior-year quarter, primarily due to additional income tax impacts related to the Kuan Yin property sales completed during the second quarter of 2026.

Adjusted EBITDA for the second quarter of 2026 was $247 million, compared to $260 million in the prior-year quarter. The decrease was driven by the anticipated higher APM costs associated with the recently resolved outage at the Washington Works site, as well as lower sales from APM's SPS Capstone™ line closure completed in the third quarter of 2025, partially offset by pricing increases across all segments.

Thermal & Specialized Solutions

Q2 2026

Q2 2025

Y-o-Y % ∆

Q1 2026

Q-o-Q % ∆

Net Sales (millions)

$591

$597

(1) %

$568

4 %

Opteon™ Refrigerants

$337

$375

(10) %

$313

8 %

Freon™ Refrigerants

$150

$123

22 %

$162

(7) %

Foam, Propellants & Other (FP&O)

$104

$99

5 %

$93

12 %

Adjusted EBITDA (millions)

$213

$207

3 %

$190

12 %

Adjusted EBITDA Margin

36 %

35 %

1 ppts

33 %

3 ppts

TSS segment second quarter 2026 Net Sales were $591 million, a decrease of 1% versus the prior-year quarter, driven by a 4% decrease in volumes, partially offset by a 2% increase in price and a slight currency tailwind.

The decrease in volumes was primarily attributable to lower stationary AC aftermarket refrigerant sales of TSS Opteon™ blends in North America, compared with elevated demand in Q2 2025 driven by the initial aftermarket channel fill associated with the stationary technology AC transition under the U.S. AIM Act, partially offset by higher Freon™ prices, primarily in automotive applications.

Adjusted EBITDA for the quarter increased 3% to $213 million, while Adjusted EBITDA Margin increased one point to 36%. The increase in Adjusted EBITDA was driven by higher pricing, aided by the timing of certain costs in the quarter.

Sequentially, TSS Net Sales increased 4%, driven by a 5% seasonal volume increase, partially offset by mix-related pricing and currency headwinds.

Titanium Technologies

Q2 2026

Q2 2025

Y-o-Y % ∆

Q1 2026

Q-o-Q % ∆

Net Sales (millions)

$661

$657

1 %

$559

18 %

  TiO2 Pigment

$639

$629

2 %

$541

18 %

  Minerals

$22

$28

(21 %)

$18

22 %

Adjusted EBITDA (millions)

$48

$47

2 %

$18

167 %

Adjusted EBITDA Margin

7 %

7 %

0 ppts

3 %

4 ppts

TT segment second quarter 2026 Net Sales were $661 million, a 1% increase compared to the prior-year quarter. The increase was driven by a 2% increase in global pricing and a 1% currency tailwind, more than offsetting a 2% decline in global volumes. Pricing increased across all regions, while the volume decline was driven by lower TiO2 sales across key end markets, with the exception of Asia, excluding China, and Latin America.

TT segment second quarter 2026 Adjusted EBITDA increased to $48 million from $47 million in the prior-year quarter, while Adjusted EBITDA Margin was flat. The increase in Adjusted EBITDA was primarily driven by the global pricing strength noted above, partially offset by higher costs due to inflation.

Sequentially, TT segment second quarter 2026 Net Sales increased 18%, driven by a 15% increase in global volumes and a 3% increase in price, reflecting continued execution of recent TiO2 pricing actions. Sequential price and volume increases were reflected across all regions.

Advanced Performance Materials

Q2 2026

Q2 2025

Y-o-Y % ∆

Q1 2026

Q-o-Q % ∆

 Net Sales (millions)

$326

$346

(6 %)

$243

34 %

Advanced Materials

$184

$214

(14 %)

$143

29 %

Performance Solutions

$142

$132

8 %

$100

42 %

Adjusted EBITDA (millions)

$26

$50

(48 %)

$5

420 %

Adjusted EBITDA Margin

8 %

14 %

(6) ppt

2 %

6 ppts

APM segment second quarter 2026 Net Sales were $326 million, a 6% decrease compared to the prior-year quarter. The decrease was driven by a 9% decrease in volumes, partially offset by a 2% increase in price and a slight currency tailwind. The volume decline was primarily driven by the APM SPS Capstone™ line closure completed in the third quarter of 2025. Performance Solutions Net Sales increased 8% year-over-year, supported by order book strength and continued momentum in high-value specialty products serving data center and semiconductor end markets.

APM segment second quarter 2026 Adjusted EBITDA decreased 48% to $26 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased six percentage points to 8%. The decrease in Adjusted EBITDA was primarily driven by lower sales associated with the SPS Capstone™ line closure, as well as higher costs from the now-resolved outage at the Washington Works site.

Sequentially, APM segment second quarter 2026 Net Sales increased approximately 34%, driven by a 31% increase in volumes reflecting more normalized operations at the Washington Works site and a 4% pricing uplift, partially offset by a slight currency headwind. Performance Solutions Net Sales increased 42% sequentially, reflecting continued order book strength and momentum in high-value specialty products serving data center and semiconductor end markets.

Other Non-Reportable Segment

The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the second quarter 2026 of $13 million and $2 million, respectively.

Corporate Expenses

Corporate Expenses were $42 million in the second quarter of 2026, a decrease of approximately $4 million compared to the prior-year quarter. This was primarily due to lower costs associated with legacy litigation activities.

Liquidity and Capital Allocation

As of June 30, 2026, consolidated gross debt was $3.9 billion. Debt, net of $671 million in unrestricted cash and cash equivalents, was $3.2 billion, resulting in a net leverage ratio of approximately 4.4x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.6 billion, comprised of $671 million in unrestricted5 cash and cash equivalents and $953 million of revolving credit facility capacity, net of outstanding letters of credit.

During the quarter, the Company paid down €230 million of the outstanding tranche of the B-3 Euro-denominated Term Loan due August 2028, using a mixture of proceeds from the previously announced Kuan Yin land sale and organic cash. The Company anticipates further debt repayments in 2026.

Operating cash flows for the second quarter of 2026 were $158 million, compared to $93 million in the prior-year quarter, highlighting improvements in net working capital performance.

Capital expenditures for the second quarter of 2026 amounted to $44 million, an increase compared to $43 million in the prior-year quarter.

Free Cash Flows for the second quarter of 2026 were $114 million, compared to $50 million in the second quarter of 2025.

Third Quarter 2026 Outlook

In the third quarter, the Company expects consolidated Net Sales to decrease in the range of 5% to flat, sequentially, driven by weaker Opteon™ blends aftermarket refrigerant demand in TSS, with consolidated Adjusted EBITDA expected to range between $175 million and $205 million. Corporate Expenses are expected to approximate $40 million to $45 million. The Company also anticipates capital expenditures to approximate $65 million, with Free Cash Flows of at least $50 million, reflecting the timing of payments for plant turnaround activities commencing later in the third quarter.

TSS expects Net Sales will sequentially decrease in the mid-teens to 20% range, driven by less favorable seasonality in connection with the 2026 cooling season in the Northern Hemisphere and weaker Opteon™ blends aftermarket refrigerant demand in North America due to elevated market inventory levels from the initial channel fill in mid-2025.  Adjusted EBITDA is expected to be between $125 million and $140 million.

TT expects a sequential Net Sales increase in the low-to-mid single-digit percentage range, driven by recent pricing announcements, with stable volumes. Adjusted EBITDA is expected to range between $70 million and $80 million.

APM expects a sequential Net Sales increase in the mid-to-high single digit percentage range, driven by a return to normal operating levels at the Washington Works facility and continued strength in the Performance Solutions order book in high-value specialty products primarily serving data center and semiconductor end markets. Adjusted EBITDA for APM is expected to be between $20 million and $30 million.

Full Year 2026 Outlook

The Company continues to expect 2026 Net Sales to grow in the range of 1% to 5% over 2025, with Adjusted EBITDA between $775 million and $825 million. Moving later into the second half, this outlook is supported by broader pricing momentum in TT with seasonal volume declines offset by anticipated cost improvements, APM's demand strength in high-value end markets supported by operational improvements driving earnings above near-term levels, and TSS aftermarket weakness driving slightly weaker earnings to end the year. Capital expenditures are anticipated to be between $250 million and $280 million, with overall Free Cash Flow Conversion above 25%, due to increased earnings and improvements in working capital throughout the year. The Company continues to anticipate achieving a net leverage ratio of around 3.8x by the end of 2026.

Conference Call

As previously announced, Chemours will hold a conference call and webcast on August 5, 2026, at 8:00 AM Eastern Daylight Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.

Non-GAAP Financial Measures

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the third quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

CONTACTS:

INVESTORS 
Brandon Ontjes 
Vice President, Head of Strategy & Investor Relations 
+1.302.773.3309
[email protected]   

NEWS MEDIA 
Cassie Olszewski
Media Relations & Reputation Leader 
+1.302.219.7140
[email protected]

1 Certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Annual Report on Form 10-K for the year ended December 31, 2025.

2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".

3 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.

4 On a diluted earnings per share basis.

5 Restricted cash approximated $52 million of the end of the second quarter of 2026, reflecting primarily escrow payments Chemours has made related to the MOU agreement with DuPont, Corteva and EID as further described in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

The Chemours Company

Consolidated Statements of Operations (Unaudited)1

(Dollars in millions, except per share amounts)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Net sales

$

1,591

$

1,615

$

2,972

$

2,983

Cost of goods sold

1,305

1,337

2,474

2,469

Gross profit

286

278

498

514

Selling, general, and administrative expense

469

424

616

547

Research and development expense

27

28

53

55

Restructuring, asset-related, and other charges

3

18

16

51

Total other operating expenses

499

470

685

653

Equity in earnings of affiliates

9

9

17

17

Interest expense, net

(68)

(67)

(137)

(133)

Loss on extinguishment of debt

(2)

—

(11)

—

Other income, net

273

2

296

6

Loss before income taxes

(1)

(248)

(22)

(249)

Provision for income taxes

273

131

281

135

Net loss

(274)

(379)

(303)

(384)

Less: Net income attributable to non-controlling interests

—

1

—

1

Net loss attributable to Chemours

$

(274)

$

(380)

$

(303)

$

(385)

Per share data

Basic (loss) earnings per share of common stock

$

(1.81)

$

(2.53)

$

(2.01)

$

(2.56)

Diluted (loss) earnings per share of common stock

(1.81)

(2.53)

(2.01)

(2.56)

The Chemours Company

Consolidated Balance Sheets (Unaudited)1

(Dollars in millions, except per share amounts)

June 30, 2026

December 31, 2025

Assets

Current assets:

Cash and cash equivalents

$

671

$

670

Restricted cash and restricted cash equivalents

—

2

Accounts and notes receivable, net

907

679

Inventories

1,452

1,569

Prepaid expenses and other

63

80

Assets held for sale

1

1

Total current assets

3,094

3,001

Property, plant, and equipment

9,993

9,920

Less: Accumulated depreciation

(6,965)

(6,842)

Property, plant, and equipment, net

3,028

3,078

Operating lease right-of-use assets

270

271

Goodwill

46

46

Other intangible assets, net

2

2

Investments in affiliates

170

160

Assets held for sale, non-current

—

21

Restricted cash and restricted cash equivalents

52

52

Other assets

488

751

Total assets

$

7,150

$

7,382

Liabilities

Current liabilities:

Accounts payable

$

937

$

954

Compensation and other employee-related cost

83

96

Short-term and current maturities of long-term debt

34

42

Current environmental remediation

124

88

Other accrued liabilities

683

506

Total current liabilities

1,861

1,686

Long-term debt, net

3,838

4,099

Operating lease liabilities

191

191

Long-term environmental remediation

671

530

Deferred income taxes

64

37

Other liabilities

573

588

Total liabilities

7,198

7,131

Commitments and contingent liabilities

Equity

Common stock (par value $0.01 per share; 810,000,000 shares authorized;
199,276,562 shares issued and 150,463,268 shares outstanding at June 30,
2026; 198,720,786 shares issued and 149,893,993 shares outstanding at
December 31, 2025)

2

2

Treasury stock, at cost (48,813,294 shares at June 30, 2026 and 48,826,793 at
December 31, 2025)

(1,801)

(1,802)

Additional paid-in capital

1,088

1,074

Retained earnings

891

1,220

Accumulated other comprehensive loss

(229)

(244)

Total Chemours stockholders' equity

(49)

250

Non-controlling interests

1

1

Total equity

(48)

251

Total liabilities and equity

$

7,150

$

7,382

The Chemours Company

Consolidated Statements of Cash Flows (Unaudited)1

(Dollars in millions)

Six Months Ended June 30,

2026

2025

Cash flows from operating activities

Net loss

$

(303)

$

(384)

Adjustments to reconcile net income to cash used for operating activities:

Depreciation and amortization

159

180

Gain on sales of assets and businesses

(266)

(1)

Equity in earnings of affiliates, net

(10)

(16)

Loss on extinguishment of debt

11

—

Amortization of debt issuance costs and issue discounts

5

6

Deferred tax provision

238

97

Asset-related charges

1

11

Stock-based compensation expense

14

12

Net periodic pension (income) cost

(1)

—

Defined benefit plan contributions

(1)

(8)

Other operating charges and credits, net

(9)

14

Decrease (increase) in operating assets:

Accounts and notes receivable, net

(218)

(174)

Inventories and other current operating assets

114

(42)

Other non-current operating assets

53

64

(Decrease) increase in operating liabilities:

Accounts payable

(12)

(87)

Other current operating liabilities

217

70

Other non-current operating liabilities

122

239

Cash provided by (used for) operating activities

114

(19)

Cash flows from investing activities

Purchases of property, plant, and equipment

(93)

(127)

Proceeds from life insurance policies

1

—

Proceeds from sales of assets and businesses

294

1

Foreign exchange contract settlements, net

(7)

(2)

Cash provided by (used for) investing activities

195

(128)

Cash flows from financing activities

Proceeds from issuance of debt

700

95

Debt repayments

(963)

(111)

Payments on finance leases

(5)

(7)

Payments of debt issuance cost

(10)

(4)

Proceeds from supplier financing program

32

47

Payments to supplier financing program

(31)

(53)

Proceeds from exercised stock options, net

3

—

Payments related to tax withholdings on vested stock awards

(2)

(1)

Payments of dividends to the Company's common shareholders

(26)

(50)

Debt extinguishment payments

(6)

—

Cash used for financing activities

(308)

(84)

Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash
equivalents

(2)

21

Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents

(1)

(210)

Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,

724

763

Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30,

$

723

$

553

Supplemental cash flows information

Non-cash investing and financing activities:

Purchases of property, plant, and equipment included in accounts payable

$

26

$

26

The Chemours Company

Segment Financial and Operating Data (Unaudited)

(Dollars in millions)

Segment Net Sales1

Three Months

Ended

Sequential

Three Months Ended June 30,

Increase /

March 31,

Increase /

2026

2025

(Decrease)

2026

(Decrease)

Thermal & Specialized Solutions

$

591

$

597

$

(6)

$

568

$

23

Titanium Technologies

661

657

4

559

102

Advanced Performance
Materials

326

346

(20)

243

83

Other Non-Reportable Segment

13

15

(2)

11

2

Total Net Sales

$

1,591

$

1,615

$

(24)

$

1,381

$

210

Segment Adjusted EBITDA1

Three Months

Ended

Sequential

Three Months Ended June 30,

Increase /

March 31,

Increase /

2026

2025

(Decrease)

2026

(Decrease)

Thermal & Specialized Solutions

$

213

$

207

$

6

$

190

$

23

Titanium Technologies

$

48

$

47

$

1

$

18

$

30

Advanced Performance
Materials

$

26

$

50

$

(24)

$

5

$

21

Other Non-Reportable Segment

$

2

$

4

$

(2)

$

3

$

(1)

Quarterly Change in Net Sales from the three months ended June 30, 2025

June 30, 2026

Percentage Change
vs.

Percentage Change Due To

Net Sales

June 30, 2025

Price

Volume

Currency

Portfolio

Total Company

$

1,591

(1)

%

2

%

(4)

%

1

%

—

%

Thermal & Specialized Solutions

$

591

(1)

%

2

%

(4)

%

1

%

—

%

Titanium Technologies

661

1

%

2

%

(2)

%

1

%

—

%

Advanced Performance
Materials

326

(6)

%

2

%

(9)

%

1

%

—

%

Other Non-Reportable Segment

13

(12)

%

(4)

%

(8)

%

—

%

—

%

Quarterly Change in Net Sales from the three months ended March 31, 2026

June 30, 2026

Percentage Change
vs.

Percentage Change Due To

Net Sales

March 31, 2026

Price

Volume

Currency

Portfolio

Total Company

$

1,591

15

%

2

%

13

%

—

%

—

%

Thermal & Specialized
Solutions

$

591

4

%

(1)

%

5

%

—

%

—

%

Titanium Technologies

661

18

%

3

%

15

%

—

%

—

%

Advanced Performance
Materials

326

34

%

4

%

31

%

(1)

%

—

%

Other Non-Reportable
Segment

13

19

%

(5)

%

24

%

—

%

—

%

The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)

GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
 GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation1

Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

Three Months Ended

Six Months Ended

Twelve Months Ended

June 30,

March 31,

June 30,

June 30,

2026

2025

2026

2026

2025

2026

2025

Loss before income taxes

$

(1)

$

(248)

$

(22)

$

(22)

$

(249)

$

(52)

$

(292)

Net loss attributable to Chemours

$

(274)

$

(380)

$

(29)

$

(303)

$

(385)

$

(303)

$

(428)

Non-operating pension and other post-
retirement benefit income

(3)

(2)

(2)

(5)

(4)

(12)

(5)

Exchange losses (gains), net

1

4

(1)

1

7

5

10

Restructuring, asset-related, and other
charges (1)

3

18

13

16

50

24

100

Goodwill impairment charge (2)

—

—

—

—

—

—

56

Loss on extinguishment of debt (3)

2

—

9

11

—

16

1

Gain on sales of assets and businesses,
net (4)

(266)

—

—

(266)

(1)

(273)

(1)

Transaction costs (5)

—

2

2

2

2

6

4

Qualified spend recovery (6)

(6)

(13)

(5)

(11)

(22)

(31)

(33)

Litigation-related charges (7)

225

293

20

244

293

272

296

Environmental charges (8)

144

60

7

150

60

184

75

Adjustments made to income taxes (9)

207

179

1

208

181

209

191

Provision for (benefit from) income taxes
relating to reconciling items (10)

31

(70)

(7)

25

(70)

8

(81)

Adjusted Net Income

64

91

8

72

111

105

185

Net income attributable to non-controlling
interests

—

1

—

—

1

(1)

1

Interest expense, net

68

67

69

137

133

273

268

Depreciation and amortization (11)

80

79

79

159

157

320

304

All remaining provision for income taxes
(10)

35

22

13

48

24

36

37

Adjusted EBITDA

$

247

$

260

$

169

$

416

$

426

$

733

$

795

Total debt principal

$

3,914

$

4,183

Less: Cash and cash equivalents

(671)

(502)

Total debt principal, net

$

3,243

$

3,681

Net Leverage Ratio (calculated using
GAAP earnings) (12)

(62.4)x

(12.6)x

Net Leverage Ratio (calculated using
Non-GAAP earnings) (12)

4.4x

4.6x

GAAP Net Loss Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation

GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)1

(1)

For the twelve months ended June 30, 2026, restructuring, asset-related and other charges primarily includes employee separation charges related to the 2026 Restructuring Program as well as charges related to our decision to exit our SPS CapstoneTM business. For the twelve months ended June 30, 2025, restructuring, asset-related and other charges primarily include charges related to our decision to exit our SPS CapstoneTM business and the 2024 Restructuring Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.

(2)

For the twelve months ended June 30, 2025, this represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025.

(3)

For the twelve months ended June 30, 2026, loss on extinguishments of debt reflects costs associated with early redemption of the 2027 senior unsecured notes and partial early redemption of our 2028 senior unsecured notes during the second quarter of 2026. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.

(4)

For the twelve months ended June 30, 2026, gain on sales of assets and businesses, net includes a gain on sale of $273 million, primarily related to certain parcels of land at the Company's manufacturing site in Kuan Yin, Taiwan. See "Note 10 - Property, Plant, and Equipment, Net" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.

(5)

For the twelve months ended June 30, 2026, transaction costs include $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.

(6)

Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

(7)

Litigation-related charges pertain to certain litigation settlements and reserves established, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended June 30, 2026 and June 30, 2025, litigation-related charges includes $256 and $289 million related to PFOA and PFAS matters, respectively. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details. 

(8)

Environmental charges pertain to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended June 30, 2026, environmental charges primarily include changes to remediation reserves related to the Consent Decree entered into with the Environmental Protection Agency, ("EPA"), as well as the West Virginia Department of Environmental Protection ("WVDEP") in the second quarter of 2026. For the twelve months ended June 30, 2025, environmental charges primarily include changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further details.

(9)

Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

(10)

The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(11)

For the twelve months ended June 30, 2025, accelerated depreciation charges of $23 million, incurred as part of our decision to exit our SPS CapstoneTM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.

(12)

Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)

GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation1

Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which include unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.

Three Months Ended

Six Months Ended

June 30,

March 31,

June 30,

2026

2025

2026

2026

2025

Numerator:

Net loss attributable to Chemours

$

(274)

$

(380)

$

(29)

$

(303)

$

(385)

Adjusted Net Income

64

91

8

72

111

Denominator:

Weighted-average number of common shares
outstanding - basic

151,225,044

150,238,691

150,767,077

150,997,325

150,078,085

Dilutive effect of the Company's employee
compensation plans (1)

1,588,513

268,070

819,728

1,204,120

379,632

Weighted-average number of common shares
outstanding - diluted (1)

152,813,557

150,506,761

151,586,805

152,201,445

150,457,717

Basic loss per share of common stock (2)

$

(1.81)

$

(2.53)

$

(0.19)

$

(2.01)

$

(2.56)

Diluted loss per share of common stock (1) (2)

(1.81)

(2.53)

(0.19)

(2.01)

(2.56)

Adjusted basic earnings per share of common
stock (2)

0.42

0.61

0.05

0.47

0.74

Adjusted diluted earnings per share of common
stock (1) (2)

0.42

0.61

0.05

0.47

0.74

(1)

In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three and six months ended June 30, 2026 and the three months ended March 31, 2026. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and six months ended June 30, 2026 and the three months ended March 31, 2026 as Adjusted Net Income was in a net income position.

(2)

Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.

The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)

GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation

Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

Three Months Ended

Six Months Ended

June 30,

March 31,

June 30,

2026

2025

2026

2026

2025

Cash flows provided by (used for)
operating activities

$

158

$

93

$

(44)

$

114

$

(19)

Less: Purchases of property, plant, and
equipment

(44)

(43)

(49)

(93)

(127)

Free Cash Flows

$

114

$

50

$

(93)

$

21

$

(146)

Adjusted EBITDA

247

260

169

416

426

Free Cash Flow Conversion

46

%

19

%

(55)

%

5

%

(34)

%

2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free
Cash Flow Conversion Reconciliation (1) 

Free Cash Flows is defined as cash flows provided by operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

Estimated

Year Ended December 31, 2026

Low

High

Cash flows provided by operating activities

$

445

$

525

Less: Purchases of property, plant, and equipment

(250)

(280)

Free Cash Flows

$

195

$

245

Adjusted EBITDA

775

825

Free Cash Flow Conversion

25

%

30

%

(1)

Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.

2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted
EBITDA Reconciliation (1)

(Estimated)

Year Ending December 31, 2026

Low

High

Net loss attributable to Chemours

$

(255)

$

(230)

Restructuring, transaction, and other costs, net (2)

375

375

Adjusted Net Income

120

145

Interest expense, net

270

280

Depreciation and amortization

320

320

All remaining provision for income taxes

65

80

Adjusted EBITDA

$

775

$

825

(1)

The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.

(2)

Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

SOURCE The Chemours Company

The settlement resolves the federal government's claims relating to discharge of PFAS compounds across three current operating sites, as well as certain environmental claims by the State of West Virginia.   Chemours is expected to pay EPA and WVDEP a $22.5 million civil penalty over a three-year period, and fund $90 million in additional mitigation projects over the next 15 years to further reduce PFAS emissions and enhance certain existing off-site drinking water programs. The settlement recognizes that Chemours has already begun planning and implementing operational improvements and remedial measures at its facilities, and contains further actions the Company will take to mitigate future emissions and enhance existing programs. This settlement provides Chemours with greater clarity on future compliance requirements and actions to support long-term responsible manufacturing. , /PRNewswire/ -- The Chemours Company (NYSE: CC) (the "Company") today announced a settlement to resolve claims asserted by the U.S. Environmental Protection Agency ("EPA") relating to PFAS discharges and other alleged non-compliance actions, primarily at the Company's Washington Works, Fayetteville Works, and Chambers Works facilities. The West Virginia Department of Environmental Protection ("WVDEP") is also a party to the settlement and joins in these releases.

The settlement agreement is the latest progress delivered under the Strengthening the Long Term pillar of Chemours' Pathway to Thrive strategy, which includes the Company's sustained efforts to address legacy PFAS and other environmental claims. The settlement also recognizes the significant work already completed or underway across Chemours' sites to reduce emissions and strengthen processes.

Under the settlement, Chemours has agreed to pay EPA and WVDEP a $22.5 million civil penalty, of which $15 million was previously accrued. This civil penalty is expected to be paid in three annual installments in 2026, 2027 and 2028, beginning within 30 days of the court's approval of the Consent Decree containing the settlement. In addition, over the next 15 years, Chemours will fund $90 million in additional mitigation projects to further reduce PFAS emissions from the operating sites or drinking water projects. Such projects support Chemours responsible manufacturing practices and will help advance the Company's Corporate Responsibility Commitment goal to reduce process emissions of fluorinated organic chemicals by 99% or more by 2030.

Further, the Company has also agreed to perform certain program and site-related actions as part of the settlement. This includes an expansion of the Company's existing off-site drinking water programs in West Virginia, Ohio, and New Jersey to incorporate learnings from Chemours' other off-site programs. The Company expects the expansion of the off-site drinking water programs will result in an increase to its existing environmental reserves.

Aligned with the Company's Pathway to Thrive strategy, Chemours continues to focus on responsibly resolving outstanding environmental and regulatory matters with terms that improve site operating certainty and include payment and remediation commitments that are structured over time. The terms of the settlement, including a further description of claims released and not released, are set forth in a proposed Consent Decree, which remains subject to final court approval.

In connection with the settlement, Chemours has also reached a resolution with the West Virginia Rivers Coalition for less than $1 million to resolve its litigation that was commenced in 2024 under the Clean Water Act alleging exceedances of certain permitted discharge limits at the Company's Washington Works facility.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. 

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the expected performance and impact of the cost-sharing arrangements by and between Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome of the final court approval process for the Consent Decree, including any appeals, the outcome of any pending or future litigation related to PFAS or PFOA, including personal injury claims and natural resource damages claims, the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of injunctive actions and mitigation projects under the Consent Decree, changes in laws and regulations applicable to PFAS chemicals, the performance by each of the parties of their respective obligations under the cost-sharing arrangement, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, Chemours' ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of the Company's products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for the Company's segments individually and the Company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, the Company's ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, the Company's ability to make acquisitions, integrate acquired businesses or assets into the Company's operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond the Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect the Company's business and operations and may or may continue to hinder the Company's ability to provide goods and services to customers, cause disruptions in the Company's supply chains such as through strikes, labor disruptions or other events, adversely affect the Company's business partners, significantly reduce the demand for the Company's products, adversely affect the health and welfare of the Company's personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that the Company is unable to identify at this time or that the Company does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025.

CONTACTS:

INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
[email protected]

NEWS MEDIA 
Cassie Olszewski
Media Relations & Reputation Leader 
+1.302.219.7140
[email protected]

SOURCE The Chemours Company